Skip to main content

Table 1 Summary of the identified studies

From: Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium avium complex pulmonary disease: a systematic review and meta-analysis

StudyStudy designCountryEnrollmentInclusion criteria*MR-MAC-PD Pts /Total Pts, n / n (%)Age, yearFemale, n (%)BMI, kg/m2FC type, n (%)Never smoker, n (%)M. intracellulare / M. avium, n (%) / n (%)
Tanaka 1999 [13]Prospective observationalJapanNov 1992 – Nov 1997>  326 / 46 (13)NA4 (67)NRNANANA
Griffith 2006 [5]Retrospective observationalUnited States1991–2005≥ 3251 / 51 (100)64.7 ± 13.628 (55)NR27 (53)18 (35)41 (77) / 12 (23)
Moon 2016 [6]Retrospective observationalSouth KoreaJan 2002 – Dec 2014≥ 3234 / 34 (100)65 (61–70)11 (32)19.7 (17.3–21.2)19 (56)20 (59)21 (62) / 13 (38)
Morimoto 2016 [7]Retrospective observationalJapanSep 2005 – Jul 2014>  3290 / 90 (100)68 (60–74)67 (74)17.4 (15.7–19.6)27 (30)67 (74)15 (17) / 50 (56)
Kadota 2016 [8]Retrospective observationalJapanJan 2009 – Jun 2013≥ 3233 / 33 (100)67 ± 931 (94)17.2 ± 5.025 (76)30 (91)NR
Yagi 2017 [14]Retrospective observationalJapanJan 2014 – May 2016≥ 329 / 26 (35)NA8 (89)NA4 (44)NA0 (0) / 9 (100)
Aznar 2018 [15]Retrospective observationalCanadaJul 2003 – Dec 2016NR8 / 54 (15)surgery 67.5 (64–69.5) non-surgery 66 (57.5–77.5)8 (100)NA0 (0)NRNA
Griffith 2018 [16]Prospective randomizedGlobalMay 2015 – Jan 2017≥ 3273 / 336 (22)NANANANRNANR
Asakura 2019 [17]Retrospective observationalJapanJan 2010 – Jul 2017≥ 3215 / 31 (48)NA12 (80)≤18.5: 9 (60%) > 18.5: 6 (40%)NANANA
  1. Note: Data are presented as mean ± standard deviation or median (interquartile range) unless otherwise indicated
  2. *Minimal inhibitory concentration of clarithromycin, μg/mL
  3. †The study was conducted at 127 clinical centers in 18 countries in North America, Asia-Pacific region, and Europe
  4. Abbreviations: MR-MAC-PD macrolide-resistant M. avium complex pulmonary disease, BMI body mass index, FC fibrocavitary, Pts patients, NR not reported in the article, NA specific data for MR-MAC-PD patients are not available